Clinical characteristics and US findings in 417 CCP+ at-risk individuals and their association with inflammatory arthritis development at 24 months follow-up
| . | . | 24-month follow-up . | . | |
|---|---|---|---|---|
| . | Overall, n = 417 . | ‘Progressors’, n = 92 . | ‘Non-progressors’, n = 325 . | P-value . |
| Age, years, median ± s.d. | 52 ± 13 | 54 ± 14 | 51 ± 13 | 0.047 |
| Female, n (%) | 304 (72.9) | 67 (72.8) | 237 (72.9) | >0.9 |
| Current or previous smoker, n (%) | 232 (55.6) | 64 (69.6) | 168 (51.7) | 0.002 |
| Hand joint tenderness on examination, n (%) | 151 (36.2) | 43 (46.7) | 108 (33.2) | 0.017 |
| Foot joint tenderness on examination, n (%) | 72 (17.3) | 21 (22.8) | 51 (15.7) | 0.11 |
| EMS ≥30 min, n (%) | 158 (37.9) | 48 (52.2) | 110 (33.8) | 0.001 |
| High anti-CCP level, n (%) | 273 (65.5) | 76 (82.6) | 197 (60.6) | <0.001 |
| RF positivity, n (%) | 158 (37.9) | 57 (62.0) | 101 (31.1) | <0.001 |
| GS abnormality in ≥1 joint, n (%) | 389 (93.3) | 87 (94.6) | 302 (92.9) | 0.6 |
| Power Doppler abnormality in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| US synovitisa in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| Bone erosions in ≥1 joint, n (%) | 48 (11.5) | 25 (27.2) | 23 (7.1) | <0.001 |
| US synovitisa and/or bone erosions in ≥1 joint, n (%) | 120 (28.8) | 51 (55.4) | 69 (21.2) | <0.001 |
| . | . | 24-month follow-up . | . | |
|---|---|---|---|---|
| . | Overall, n = 417 . | ‘Progressors’, n = 92 . | ‘Non-progressors’, n = 325 . | P-value . |
| Age, years, median ± s.d. | 52 ± 13 | 54 ± 14 | 51 ± 13 | 0.047 |
| Female, n (%) | 304 (72.9) | 67 (72.8) | 237 (72.9) | >0.9 |
| Current or previous smoker, n (%) | 232 (55.6) | 64 (69.6) | 168 (51.7) | 0.002 |
| Hand joint tenderness on examination, n (%) | 151 (36.2) | 43 (46.7) | 108 (33.2) | 0.017 |
| Foot joint tenderness on examination, n (%) | 72 (17.3) | 21 (22.8) | 51 (15.7) | 0.11 |
| EMS ≥30 min, n (%) | 158 (37.9) | 48 (52.2) | 110 (33.8) | 0.001 |
| High anti-CCP level, n (%) | 273 (65.5) | 76 (82.6) | 197 (60.6) | <0.001 |
| RF positivity, n (%) | 158 (37.9) | 57 (62.0) | 101 (31.1) | <0.001 |
| GS abnormality in ≥1 joint, n (%) | 389 (93.3) | 87 (94.6) | 302 (92.9) | 0.6 |
| Power Doppler abnormality in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| US synovitisa in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| Bone erosions in ≥1 joint, n (%) | 48 (11.5) | 25 (27.2) | 23 (7.1) | <0.001 |
| US synovitisa and/or bone erosions in ≥1 joint, n (%) | 120 (28.8) | 51 (55.4) | 69 (21.2) | <0.001 |
US synovitis was defined as the concomitant presence of GS changes ≥1 and power Doppler ≥1 in the same joint. EMS: early morning stiffness; GS: greyscale.
Clinical characteristics and US findings in 417 CCP+ at-risk individuals and their association with inflammatory arthritis development at 24 months follow-up
| . | . | 24-month follow-up . | . | |
|---|---|---|---|---|
| . | Overall, n = 417 . | ‘Progressors’, n = 92 . | ‘Non-progressors’, n = 325 . | P-value . |
| Age, years, median ± s.d. | 52 ± 13 | 54 ± 14 | 51 ± 13 | 0.047 |
| Female, n (%) | 304 (72.9) | 67 (72.8) | 237 (72.9) | >0.9 |
| Current or previous smoker, n (%) | 232 (55.6) | 64 (69.6) | 168 (51.7) | 0.002 |
| Hand joint tenderness on examination, n (%) | 151 (36.2) | 43 (46.7) | 108 (33.2) | 0.017 |
| Foot joint tenderness on examination, n (%) | 72 (17.3) | 21 (22.8) | 51 (15.7) | 0.11 |
| EMS ≥30 min, n (%) | 158 (37.9) | 48 (52.2) | 110 (33.8) | 0.001 |
| High anti-CCP level, n (%) | 273 (65.5) | 76 (82.6) | 197 (60.6) | <0.001 |
| RF positivity, n (%) | 158 (37.9) | 57 (62.0) | 101 (31.1) | <0.001 |
| GS abnormality in ≥1 joint, n (%) | 389 (93.3) | 87 (94.6) | 302 (92.9) | 0.6 |
| Power Doppler abnormality in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| US synovitisa in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| Bone erosions in ≥1 joint, n (%) | 48 (11.5) | 25 (27.2) | 23 (7.1) | <0.001 |
| US synovitisa and/or bone erosions in ≥1 joint, n (%) | 120 (28.8) | 51 (55.4) | 69 (21.2) | <0.001 |
| . | . | 24-month follow-up . | . | |
|---|---|---|---|---|
| . | Overall, n = 417 . | ‘Progressors’, n = 92 . | ‘Non-progressors’, n = 325 . | P-value . |
| Age, years, median ± s.d. | 52 ± 13 | 54 ± 14 | 51 ± 13 | 0.047 |
| Female, n (%) | 304 (72.9) | 67 (72.8) | 237 (72.9) | >0.9 |
| Current or previous smoker, n (%) | 232 (55.6) | 64 (69.6) | 168 (51.7) | 0.002 |
| Hand joint tenderness on examination, n (%) | 151 (36.2) | 43 (46.7) | 108 (33.2) | 0.017 |
| Foot joint tenderness on examination, n (%) | 72 (17.3) | 21 (22.8) | 51 (15.7) | 0.11 |
| EMS ≥30 min, n (%) | 158 (37.9) | 48 (52.2) | 110 (33.8) | 0.001 |
| High anti-CCP level, n (%) | 273 (65.5) | 76 (82.6) | 197 (60.6) | <0.001 |
| RF positivity, n (%) | 158 (37.9) | 57 (62.0) | 101 (31.1) | <0.001 |
| GS abnormality in ≥1 joint, n (%) | 389 (93.3) | 87 (94.6) | 302 (92.9) | 0.6 |
| Power Doppler abnormality in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| US synovitisa in ≥1 joint, n (%) | 103 (24.7) | 45 (48.9) | 58 (17.8) | <0.001 |
| Bone erosions in ≥1 joint, n (%) | 48 (11.5) | 25 (27.2) | 23 (7.1) | <0.001 |
| US synovitisa and/or bone erosions in ≥1 joint, n (%) | 120 (28.8) | 51 (55.4) | 69 (21.2) | <0.001 |
US synovitis was defined as the concomitant presence of GS changes ≥1 and power Doppler ≥1 in the same joint. EMS: early morning stiffness; GS: greyscale.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
